Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.88 USD | +2.79% | -13.19% | -49.54% |
Apr. 15 | RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating | MT |
Apr. 11 | Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating | MT |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.6 for the 2024 fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-49.54% | 388M | C+ | ||
-3.20% | 184B | C+ | ||
-1.41% | 107B | C | ||
-3.63% | 67.78B | A | ||
+1.52% | 50.66B | B- | ||
+11.75% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+2.56% | 26.3B | B | ||
+2.57% | 26.04B | A- | ||
+15.06% | 25.4B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NVRO Stock
- Ratings Nevro Corp.